Use of Glucose Rate of Change Arrows to Adjust Insulin Therapy Among Individuals with Type 1 Diabetes Who Use Continuous Glucose Monitoring

Diabetes Technology & Therapeutics
Jeremy Pettus, Steven V Edelman

Abstract

This study was performed to understand and to compare differences in utilization of continuous glucose monitoring (CGM) and the rate of change (ROC) arrow to adjust insulin therapy among individuals with type 1 diabetes (T1D), comparing those treated with multiple daily insulin injections (MDI) with those treated with continuous subcutaneous insulin infusion (CSII). We surveyed 222 T1D individuals who regularly used real-time CGM to obtain information about general CGM use and response to glucose ROC arrows in managing their diabetes. The survey was completed by 222 T1D individuals. Respondents included CSII (n = 166) and MDI (n = 56) users. MDI and CSII respondents reported similar substantial increases in correction dosages (from 220 mg/dL to 120 mg/dL) in response to increasing glucose (one ROC arrow up: rising 2-3 mg/dL/min): +120% and +108%, respectively (P = 0.13). MDI and CSII respondents reported similar substantial increases in correction dosages in response to rapidly increasing glucose (two arrows up: rising >3 mg/dL/min): +146% and +138%, respectively (P = 0.72). When correcting from 220 mg/dL to 120 mg/dL, MDI respondents reported larger correction dosage reductions than CSII respondents in response to decreasing g...Continue Reading

References

Jun 15, 2007·Diabetes Technology & Therapeutics·Timothy S BaileySatish K Garg
Jan 29, 2008·Pediatric Diabetes·UNKNOWN Diabetes Research In Children Network (DirecNet) Study GroupRoy Beck
Sep 10, 2008·The New England Journal of Medicine·William V TamborlaneDongyuan Xing
Apr 23, 2009·The Journal of Clinical Endocrinology and Metabolism·Irl B Hirsch
Jul 1, 2010·The New England Journal of Medicine·Richard M BergenstalUNKNOWN STAR 3 Study Group
Feb 22, 2011·Diabetes Care·Tadej BattelinoJan Bolinder
Mar 2, 2011·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Thomas C BlevinsCaitlin Rothermel
Oct 7, 2011·The Journal of Clinical Endocrinology and Metabolism·David C KlonoffUNKNOWN Endocrine Society
Jun 15, 2012·Diabetes Technology & Therapeutics·Giulio FrontinoGiuseppe Chiumello
Feb 27, 2015·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Jeremy PettusSteven V Edelman

❮ Previous
Next ❯

Citations

Nov 9, 2016·Endocrinology and Metabolism Clinics of North America·Elena Toschi, Howard Wolpert
Feb 14, 2017·Diabetes Technology & Therapeutics·Bruce W Bode, Tadej Battelino
Feb 6, 2017·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Jeremy Pettus
May 26, 2017·Diabetes Technology & Therapeutics·David Slattery, Pratik Choudhary
May 26, 2017·Diabetes Technology & Therapeutics·Timothy S Bailey
Jan 16, 2018·Journal of Diabetes Science and Technology·Mary Binsu AbrahamUNKNOWN PLGM study group
Sep 9, 2017·Journal of Diabetes Science and Technology·David C Klonoff, David Kerr
Jun 1, 2018·Journal of Diabetes Science and Technology·Giacomo CapponGiovanni Sparacino
Feb 18, 2020·Journal of Diabetes Science and Technology·Ralph ZieglerBernd Kulzer
Aug 18, 2016·Journal of Diabetes Science and Technology·Jeremy Pettus, Steven V Edelman
Jan 20, 2016·Diabetes Technology & Therapeutics·Satish K Garg
Aug 2, 2018·Diabetes Technology & Therapeutics·Guido FreckmannCornelia Haug
Dec 14, 2018·The Diabetes Educator·Davida F KrugerChristopher G Parkin
Sep 22, 2021·Diabetes Technology & Therapeutics·Irl B Hirsch, Eden Miller

❮ Previous
Next ❯

Software Mentioned

SurveyGizmo
SAS

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.

© 2022 Meta ULC. All rights reserved